Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study

被引：0
|
作者：
Ching-Liang Ho
Tsu-Yi Chao
Chia-Lun Chang
Hsuan-Yu Lin
机构：
[1] Tri-Service General Hospital,Division of Hematology and Oncology
[2] National Defense Medical Center,Division of Hematology and Oncology
[3] Taipei Tzu Chi Hospital,Division of Hematology and Oncology
[4] Buddhist Tzu Chi Medical Foundation,Division of Hematology and Oncology
[5] Taipei Medical University-Shuang Ho Hospital,Division of Hematology and Oncology, Department of Internal Medicine
[6] Ministry of Health and Welfare,undefined
[7] Taipei Municipal Wanfang Hospital,undefined
[8] Changhua Christian Hospital,undefined
来源：
BioDrugs | 2024年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：287 / 299
页数：12
相关论文
共 50 条
  • [1] Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia-Lun
    Lin, Hsuan-Yu
    BIODRUGS, 2024, 38 (02) : 287 - 299
  • [2] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
    O'Malley, David M.
    Oaknin, Ana
    Monk, Bradley J.
    Selle, Frederic
    Rojas, Carlos
    Gladieff, Laurence
    Berton, Dominique
    Leary, Alexandra
    Moore, Kathleen N.
    Estevez-Diz, Maria D. P.
    Hardy-Bessard, Anne-Claire
    Alexandre, Jerome
    Opperman, Christina P.
    de Azevedo, Carla Rameri A. S.
    Randall, Leslie M.
    Feliu, Waldo Ortuzar
    Ancukiewicz, Marek
    Ray-Coquard, Isabelle
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 274 - 280
  • [4] A PHASE 1 STUDY OF SERPLULIMAB (A NOVEL ANTI-PD-1 ANTIBODY) IN COMBINATION WITH HLX04 (AN ANTI-VEGF ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Guo, Y.
    Li, J.
    Li, Q.
    Xue, J.
    Xue, L.
    Ge, X.
    Lin, F.
    Zhao, W.
    Tang, W.
    Peng, D.
    Wang, Q.
    Zhu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S29 - S30
  • [5] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shibata, Takashi
    Tamura, Yosuke
    Seki, Yoshitaka
    Honda, Kazunori
    Tanabe, Yuko
    Wakui, Hiroshi
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
  • [6] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 207 - 216
  • [7] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [8] A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
    Voskoboynik, Mark
    Richardson, Gary Edward
    Mileshkin, Linda R.
    McNeil, Catriona M.
    Horvath, Lisa
    Benedetti, Fabio M.
    Choy, Gavin S.
    Sankar, Neil
    McCurry, Shelly
    Zhang, Xiaoling
    Gao, Min
    Shah, Ajit K.
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] A phase 1 study of the safety, tolerability, and pharmacokinetics (PK) of MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors
    Lakhani, Nehal
    Mehnert, Janice M.
    Rasco, Drew
    Gordon, Michael
    Lohr, Joanna
    Pencheva, Pepi
    Sharma, Sharad
    Li, Hua
    LaMotte-Mohs, Ross
    Moore, Paul
    Sun, Jichao
    Sumrow, Bradley
    Wigginton, Jon
    Powderly, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [10] A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors
    Wei, Xiao-Li
    Ren, Chao
    Wang, Feng-Hua
    Zhang, Yang
    Zhao, Hong-Yun
    Zou, Ben-Yan
    Wang, Zhi-Qiang
    Qiu, Miao-Zhen
    Zhang, Dong-Sheng
    Luo, Hui-Yan
    Wang, Feng
    Yao, Sheng
    Xu, Rui-Hua
    CANCER COMMUNICATIONS, 2020, 40 (08) : 345 - 354
12345